Replies to post #136301 on Biotech Values

[mcbio]

The significance of the move for me lies as much in what it says about the FDA's attitude to the NDA as it does about the market. (Folks will recall that the reason for the original restriction were safety concerns from an earlier trial that now seem to have been resolved).

Completely agree with that take. One wouldn't think the FDA would be inclined to significantly lower the age of the target population if they were otherwise going to reject the NDA. (Obviously doesn't guarantee approval but I agree with you that it's a very good sign.)

Very likely munch candidate in my view.

Along with this good news today, DVAX market cap is now above $500M. So, the key of course is what's a reasonable munch price? You think they could fetch a cool $1B (or more) in a takeout? I'd much rather DVAX be around $300M market cap here but I'm cheap. ; ) Still, very good news today and I just wonder what further upside is if a buyout should occur. (Guess part of this is based on how much of that estimated $1B market you think Heplisav can now capture.)

[dav1234]

DVAX's forms 4s 1 hour ago, looks like excercise only ,no selling

[JJM760]

The significance of the move for me lies as much in what it says about the FDA's attitude to the NDA as it does about the market. (Folks will recall that the reason for the original restriction were safety concerns from an earlier trial that now seem to have been resolved).

Very likely munch candidate in my view.

Peter

DVAX starting to get a pulse again.